GI Insights

The role of diet and nutrition in irritable bowel syndrome (IBS) has long been established, but clinical updates are always evolving. That’s why Dr. Peter Buch welcomes Dr. William Chey, Professor of Medicine and Chief of Gastroenterology at the University of Michigan, to talk about the latest clinical updates from the American Gastroenterological Association.

Gastric emptying tests may be used for patients with gastroparesis and functional dyspepsia. But when it comes to assessing patients with symptoms, is it time to discard these tests? Find out with Dr. Peter Buch as he speaks with Dr. Reena Chokshi, Assistant Professor at Baylor College of Medicine and author of an editorial on this topic, titled Is It Time to Abandon Gastric Emptying in Patients With Symptoms of Gastroparesis and Functional Dyspepsia?, which was published in the Clinical Gastroenterology and Hepatology journal in May 2021.

What non-invasive techniques are available to assess liver fibrosis? Joining Dr. Peter Buch to give us insight on this key question, along with how we can incorporate these treatments into our patient care, is Dr. Maurizio Bonacini. Dr. Bonacini is an Associate Professor of Clinical Medicine at the University of California, San Francisco and CEO of Mission Gastroenterology and Hepatology.

What are our treatment options for hepatitis B, and do they have any limitations? Here to walk us through the challenges treatment landscape for hepatitis B is Dr. Robert Wong, who is a Clinical Associate Professor at Stanford University.

This program discusses the role of endothelin-receptor antagonists and their unique function and role in the management of resistant hypertension, beyond their known role in the management of pulmonary arterial hypertension. More specifically, the education will focus on the worsened prognosis associated with diagnostic delay, the challenges with current treatment modalities, the lack of guidelines being updated to reflect current clinical practices, and providing the community with a more in-depth and better understanding of the profiles associated with endothelin-receptor antagonists.

This program discusses the role of endothelin-receptor antagonists and their unique function and role in the management of resistant hypertension, beyond their known role in the management of pulmonary arterial hypertension. More specifically, the education will focus on the worsened prognosis associated with diagnostic delay, the challenges with current treatment modalities, the lack of guidelines being updated to reflect current clinical practices, and providing the community with a more in-depth and better understanding of the profiles associated with endothelin-receptor antagonists.

Hydrogen breath tests can help clinicians determine if a patient has conditions that can affect their digestive health, and they’re especially important for the diagnosis of carbohydrate maldigestion and small intestinal bacterial overgrowth. That’s why Dr. Peter Buch takes an in-depth look at breath testing with Dr. Mark Pimentel, Professor of Medicine at the David Geffen School of Medicine at UCLA and Associate Professor at Cedars-Sinai Medical Center.

In contrast to traditional monoclonal antibodies or small molecules, hyperbaric oxygen therapy involves a different type of treatment. But is this therapeutic option effective for our ulcerative colitis patients? To better understand this, Dr. Neil Nandi speaks with Dr. Parambir Dulai from Northwestern University to share his research on hyperbaric oxygen therapy.

Have you ever wondered what the practice of gastroenterology will look like in 10 years? If so, you’re not alone. And to help clear up that crystal ball, Dr. Peter Buch speaks with Dr. Eamonn Quigley about what’s to come in gastroenterology.

The treatment landscapes for alcoholic hepatitis and acute kidney injury in cirrhosis are evolving. So how are we now defining acute kidney injury with cirrhosis, and how should we treat these two conditions based on the latest therapeutic updates? To find out, Dr. Peter Buch speaks with Dr. Paul Kwo, Professor of Medicine and Director of Hepatology at Stanford University.